The investigation demonstrates that when hyperactive AKT is targeted by direct inhibition of AKT activity or by reactivating PP2A phosphatase, it may act as a potential treatment strategy for ALDOB-deficient human cancers. The gene discussed is AKT1; the disease is cancer.